Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: The effect of long-term lamivudine therapy

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 11, 2005, Pages 1349-1356

  Buti, M ^a   Jardi, R ^a   Rodriguez Frias, F ^a   Valdes, A ^a   Schaper, M ^a   Esteban, R ^a   Guardia, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS E ANTIGEN; LAMIVUDINE;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; DRUG EFFECT; DRUG FATALITY; DRUG TOLERABILITY; FATIGUE; FEMALE; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER DYSFUNCTION; LONG TERM CARE; MALAISE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; TREATMENT OUTCOME; VIRUS GENE; WILD TYPE;

ADULT; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LONG-TERM CARE; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE INHIBITORS;

EID: 20444505924     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02503.x     Document Type: Article

References (35)

1. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9: 52-61.
2. Hadziyannis S. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995; 1: 7-36.
3. Naoumov NV, Scheinder R, Grotzinger T, et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992; 102: 538-43.
4. Brunetto MR, Olivieri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibodies to hepatitis B e antigen. Hepatology 1989; 10: 198-202.
5. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutations preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-91.
6. Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91: 4077-81.
7. Dienstag J, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-61.
8. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
9. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 30: 1082-7.
10. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV-DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 300-6.
11. Tassopoulos NC, Volpes R, Pastore G, et al. Post lamivudine treatment follow-up of patients with HBeAg-negative chronic hepatitis B. J Hepatol 1999; 30 (Suppl. 1): 117.
12. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-51.
13. Buti M, Cortina M, Jardi R, et al. Two years of lamivudine therapy in anti-HBe positive patients with chronic hepatitis B. J Viral Hepat 2001; 8: 270-5.
14. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-91.
15. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-7.
16. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 1670-7.
17. Lai C-L, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
18. Zoulim F, Trepo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 1998; 29: 151-68.
19. Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32: 1145-53.
20. Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000; 32: 1163-9.
21. Jardi R, Rodriguez F, Buti M, et al. Quantitative detection of hepatitis B virus DNA in serum by a new rapid real-time fluorescence PCR assay. J Viral Hepat 2001; 8: 465-71.
22. Rodriguez-Frias F, Buti M, Jardi R, et al. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995; 22: 1641-7.
23. Stuyver L, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751-7.
24. Zoulim F, Trepo C. Is lamivudine effective on precore/core promoter mutants of hepatitis B virus? Hepatology 2000; 32: 1172-3.
25. Suzuki F, Suzuki Y, Tsubota A, et al. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5 years of lamivudine therapy. J Hepatol 2003; 37: 824-30.
26. Cianco A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B. Identification of HBV DNA sequences that are predictive of response to lamivudine. Hepatology 2004; 39: 64-73.
27. Lok AS, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during antiviral therapy: evaluation and performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2000; 40: 3729-34.
28. Jardi R, Rodríguez-Frias F, Buti M, et al. Mutations in the basic core promoter region of hepatitis B. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers. J Hepatol 2004; 40: 507-14.
29. Chen RY, Edwards R, Shaw T, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37: 27-35.
30. Stuyver L, Van Geyt C, De Gendt S, et al. Line probe assay for monitoring drug resistance in hepatitis B virus infected patients during antiviral therapy. J Clin Microbiol 2000; 38: 702-7.
31. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997; 26: 1393-5.
32. Si Ahmed SN, Tavan D, Pichoud C, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations under in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078-88.
33. Melegari N, Scaglioni P, Wands J. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1999; 27: 628-33.
34. Fu L, Cheng Y-C. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol 1998; 55: 1567-72.
35. Grandjacques C, Pradat P, Stuyver M, et al. Rapid detection of genotypes and precore mutations in the precore promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000; 33: 430-9.